Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib

Blood

Volumn 123, Issue 9, 2014, Pages 1353-1360

  Hughes, Timothy P ^a,b   Saglio, Giuseppe ^c   Kantarjian, Hagop M ^d   Guilhot, François ^e   Niederwieser, Dietger ^f   Rosti, Gianantonio ^g   Nakaseko, Chiaki ^h   De Souza, Carmino Antonio ⁱ   Kalaycio, Matt E ^j   Meier, Stephan ^k   Fan, Xiaolin ^k   Menssen, Hans D ^k   Larson, Richard A ^l   Hochhaus, Andreas ^m  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b Australia   (Australia)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e POITIERS UNIVERSITY HOSPITAL   (France)

^f UNIVERSITY OF LEIPZIG   (Germany)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h CHIBA UNIVERSITY HOSPITAL   (Japan)

ⁱ UNIVERSITY OF CAMPINAS   (Brazil)

^j LERNER RESEARCH INSTITUTE   (United States)

^k NOVARTIS PHARMA AG   (Switzerland)

^l UNIVERSITY OF CHICAGO   (United States)

^m JENA UNIVERSITY HOSPITAL   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; NILOTINIB;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CHROMOSOME ABERRATION; CHRONIC MYELOID LEUKEMIA; CLONAL EVOLUTION; CONTROLLED STUDY; DRUG EXPOSURE; DRUG INTERMITTENT THERAPY; DRUG TREATMENT FAILURE; EARLY MOLECULAR RESPONSE; FOLLOW UP; HIGH SOKAL RISK SCORE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PHILADELPHIA 1 CHROMOSOME; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RISK ASSESSMENT; SCORING SYSTEM; SPLEEN SIZE; SPLENOMEGALY; THROMBOCYTE COUNT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BENZAMIDES; DOWN-REGULATION; FOLLOW-UP STUDIES; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NEOADJUVANT THERAPY; PIPERAZINES; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84897007532     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-06-510396     Document Type: Article

References (26)

1. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2(5):561-566.
2. Hochhaus A, O'Brien SG, Guilhot F, et al IRIS Investigators. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23(6):1054-1061.
3. Hughes TP, Hochhaus A, Branford S, et al; IRIS investigators. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010;116(19):3758-3765.
4. Branford S, Seymour JF, Grigg A, et al. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res. 2007;13(23):7080-7085. (Pubitemid 350276891)
5. Quintás-Cardama A, Kantarjian H, Jones D, et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood. 2009;113(25):6315-6321.
6. Marin D, Ibrahim AR, Lucas C, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012;30(3):232-238.
7. Hanfstein B, Müller MC, Hehlmann R, et al SAKK; German CML Study Group. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia. 2012;26(9):2096-2102.
8. Jain P, Kantarjian H, Nazha A, et al. Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood. 2013;121(24):4867-4874.
9. Marin D, Hedgley C, Clark RE, et al. Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib. Blood. 2012;120(2):291-294.
10. Neelakantan P, Gerrard G, Lucas C, et al. Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. Blood. 2013;121(14):2739-2742.
11. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872-884.
12. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. Version 1, 2014. http://www.nccn.org/ professionals/physician-gls/pdf/cml.pdf. Accessed October 10, 2013.
13. Saglio G, Kim DW, Issaragrisil S, et al ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251-2259.
14. Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12(9):841-851.
15. Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012;26(10):2197-2203.
16. Cross NCP, White HE, Müller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia. 2012;26(10):2172-2175.
17. Branford S, Kim DW, Soverini S, et al. Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosomepositive chronic myeloid leukemia in chronic phase treated with nilotinib. J Clin Oncol. 2012;30(35):4323-4329.
18. Etienne G, Nicolini FE, Dulucq S, et al. Achieving a complete molecular remission under imatinib therapy is associated with a better outcome in chronic phase chronic myeloid leukaemia patients on imatinib frontline therapy [abstract]. Blood. 2012;120(21). Abstract 3754.
19. Falchi L, Kantarjian HM, Quintas-Cardama A, et al. Clinical significance of deeper molecular responses with four modalities of tyrosine kinase inhibitors as frontline therapy for chronic myeloid leukemia [abstract]. Blood. 2012;120(21). Abstract 164.
20. Hehlmann R, Lauseker M, Hanfstein B, et al. Complete molecular remission (CMR 4.5) of CML is induced faster by dose - optimized imatinib predicts better survival - results from the randomized CML-Study IV [abstract]. Blood. 2012;120(21). Abstract 67.
21. Verma D, Kantarjian HM, Shan J, et al. Sustained complete molecular response to imatinib in chronic myeloid leukemia (CML): a target worth aiming and achieving [abstract]? Blood. 2009;114(22). Abstract 505.
22. Lee SE, Choi SY, Bang JH, et al. BCR-ABL kinetics after discontinuation of imatinib in CML patients with MR4.5 or undetectable molecular residual disease [abstract]. Haematologica. 2012;97(s1):80. Abstract 200.
23. ClinicalTrials.gov. Nilotinib treatment-free remission study in CML (chronic myeloid leukemia) patients (ENESTFreedom). http://www.clinicaltrials. gov/show/NCT01784068. Accessed October 11, 2013.
24. Rousselot P, Charbonnier A, Cony-Makhoul P, et al. Loss of major molecular response is accurate for restarting imatinib after imatinib discontinuation in CP-CML patients with long lasting CMR: importance of fluctuating values of MRD and interferon [abstract]. Haematologica. 2012;97(s1):77. Abstract 194.
25. Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122(4):515-522.
26. Yeung DT, Osborn MP, White DL, et al. Early switch to nilotinib does not overcome the adverse outcome for CML patients failing to achieve early molecular response on imatinib, despite excellent overall outcomes in the TIDEL-II trial [abstract]. Blood. 2012;120(21). Abstract 3771.